Division of Cardiac Surgery, Cardiovascular Outcomes Research Laboratories (CORELAB), UCLA David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Division of Cardiac Surgery, Cardiovascular Outcomes Research Laboratories (CORELAB), UCLA David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; Department of General Surgery, University of California, Orange, California.
J Surg Res. 2019 Nov;243:481-487. doi: 10.1016/j.jss.2019.06.045. Epub 2019 Aug 1.
Left ventricular assist devices (LVADs) are increasingly used to supplant the limited number of orthotopic heart transplantation (OHT). The present study aimed to perform a contemporary analysis of emergency abdominal operations after LVAD and OHT at a national level.
The 2005-2015 National Impatient Sample, the largest all-payer hospitalization database in the United States, was used to identify all adult patients who had received LVAD or OHT. The primary outcome of interest was the rate of emergency general surgery (EGS), which included laparotomy, small or large bowel resection, peptic ulcer operation, adhesiolysis, and cholecystectomy, during the same hospitalization as LVAD or OHT. Logistic regression was used to determine risk factors for EGS as well as the association between EGS and mortality in both the LVAD and OHT populations.
Of the estimated 19,395 OHT and 23,441 LVAD performed, 445 (2.3%) OHT and 719 (3.1%) LVAD patients required EGS. The incidence of EGS in LVAD decreased from 5.4 to 3.3%, whereas it increased among OHT patients from 1.9 to 3.7%, P = 0.003. Occurrence of EGS after OHT and LVAD was associated with significantly higher inpatient risk-adjusted mortality (OHT adjusted odds ratio, 3.0; P = 0.004; LVAD adjusted odds ratio, 2.5; P < 0.001), incremental hospitalization costs (OHT, $106,778; P < 0.001; LVAD, $61,965; P < 0.001), and length of stay (OHT, 27.9 d; P < 0.001; LVAD, 20.8 d; P < 0.001).
EGS remains an infrequent but high mortality and cost complication of OHT and LVAD. Further investigation of the impact of immunosuppression, anticoagulation, and perfusion strategies on incidence of abdominal complications is warranted.
左心室辅助装置(LVAD)越来越多地被用于替代数量有限的原位心脏移植(OHT)。本研究旨在对全国范围内 LVAD 和 OHT 后紧急腹部手术进行当代分析。
使用 2005-2015 年美国最大的全支付住院患者数据库国家住院患者样本(National Inpatient Sample),确定所有接受 LVAD 或 OHT 的成年患者。主要观察结果是同一住院期间接受紧急普通外科手术(EGS)的比例,包括剖腹手术、小肠或大肠切除术、胃溃疡手术、粘连松解术和胆囊切除术。使用逻辑回归确定 EGS 的危险因素以及 EGS 与 LVAD 和 OHT 人群死亡率之间的关系。
在估计的 19395 例 OHT 和 23441 例 LVAD 中,445 例(2.3%)OHT 和 719 例(3.1%)LVAD 患者需要 EGS。LVAD 中 EGS 的发生率从 5.4%降至 3.3%,而 OHT 患者的发生率从 1.9%增至 3.7%,P=0.003。OHT 和 LVAD 后 EGS 的发生与显著更高的住院风险调整死亡率相关(OHT 调整优势比,3.0;P=0.004;LVAD 调整优势比,2.5;P<0.001),增量住院费用(OHT,106778 美元;P<0.001;LVAD,61965 美元;P<0.001)和住院时间(OHT,27.9 天;P<0.001;LVAD,20.8 天;P<0.001)。
EGS 仍然是 OHT 和 LVAD 的一种罕见但高死亡率和高成本的并发症。需要进一步研究免疫抑制、抗凝和灌注策略对腹部并发症发生率的影响。